NCT00332605

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

A Double-Blind Study of N-Acetyl Cysteine Plus Naltrexone in the Treatment of Methamphetamine Dependence

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in combination with naltrexone in methamphetamine dependence.

Detailed description

Forty subjects with DSM-IV methamphetamine dependence will receive 8 weeks of double-blind combination medication (NAC plus naltrexone) or placebo. The hypothesis to be tested is that NAC plus naltrexone will be effective and well tolerated in patients with methamphetamine dependence compared to placebo. The proposed study will provide needed data on the treatment of a public health crisis that currently lacks a clearly effective treatment.

Conditions

• Methamphetamine Dependence

Interventions

Type	Name	Description
DRUG	Naltrexone plus N-Acetyl Cysteine	daily
DRUG	Placebo	daily

Timeline

• Start date: 2006-06-01
• Primary completion: 2009-12-01
• Completion: 2010-01-01
• First posted: 2006-06-01
• Last updated: 2022-08-23
• Results posted: 2013-07-24

Locations

1 site across 1 country: United States